Literature DB >> 6205795

Evidence for an effect of antithyroid drugs on the natural history of Graves' disease.

A P Weetman, A M McGregor, R Hall.   

Abstract

In the United Kingdom, about half the patients with Graves' disease who are given antithyroid drugs are still in remission one year after treatment is stopped. The most widely held view is that such remission rates are due only to the biochemical effects of the drugs, the disease either spontaneously remitting or abating when the immune system is no longer subject to the stimulatory effects of excessive thyroid hormone. We review here the accumulating evidence against both of these alternatives. In contrast, there is now a large body of work which shows that thyrotrophin receptor antibody levels, central to the aetiology of Graves' hyperthyroidism, fall during antithyroid treatment and that remission may be related to this fall in a fashion which is dependent on the dose and duration of treatment. This immunosuppressive effect is supported by experimental data and on the basis of these results we propose that antithyroid drugs may modify the natural history of Graves' disease and contribute to the remission which occurs in a proportion of treated patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205795     DOI: 10.1111/j.1365-2265.1984.tb03456.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

Review 1.  Diagnosis and management of thyrotoxicosis.

Authors:  Elizabeth N Pearce
Journal:  BMJ       Date:  2006-06-10

Review 2.  The role of surgery in primary hyperthyroidism.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

3.  Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.

Authors:  F A Karlsson; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 4.  Thymic hyperplasia in patients with Graves' disease.

Authors:  M Dalla Costa; F A Mangano; C Betterle
Journal:  J Endocrinol Invest       Date:  2014-08-23       Impact factor: 4.256

5.  Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease.

Authors:  A P Weetman; S B Cohen; D A Oleesky; B P Morgan
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

6.  Thymic lymphoid hyperplasia with Graves' disease in a 28-year-old female: a case report.

Authors:  Kai Zhang; Weibin Wu; Yonghui Wu; Mingjun Bai; Xiaojun Li; Jian Zhang; Lijiai Gu; Huiguo Chen
Journal:  Gland Surg       Date:  2020-04

7.  Thyroid-stimulating immunoglobulins and thyroid function tests in two siblings with neonatal thyrotoxicosis.

Authors:  J M Wit; B Rees-Smith; F M Creagh; H W Bruinse; D van der Heide; R Docter; L J Gerards
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

8.  Thyroid peroxidase forms thionamide-sensitive homodimers: relevance for immunomodulation of thyroid autoimmunity.

Authors:  David O McDonald; Simon H S Pearce
Journal:  J Mol Med (Berl)       Date:  2009-08-08       Impact factor: 4.599

9.  Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.

Authors:  S Mariotti; P Caturegli; G Barbesino; G F Del Prete; L Chiovato; A Pinchera
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

10.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.